What is the latest evidence on mavacamten (cardiac myosin inhibitor) for treating symptomatic obstructive hypertrophic cardiomyopathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mavacamten: Latest Evidence for Obstructive Hypertrophic Cardiomyopathy

Mavacamten is now a Class 1 (recommended) treatment option for adults with symptomatic obstructive HCM who remain symptomatic despite beta-blockers or non-dihydropyridine calcium channel blockers, representing a major shift in management strategy. 1

FDA-Approved Indication

Mavacamten is FDA-approved specifically for adults with symptomatic NYHA class II-III obstructive HCM to improve functional capacity and symptoms. 2 This cardiac myosin inhibitor works by decreasing actin-myosin interaction, thereby reducing cardiac contractility and left ventricular outflow tract (LVOT) obstruction. 1

Current Guideline Recommendations

Treatment Algorithm

For symptomatic obstructive HCM patients:

  • First-line therapy: Beta-blockers or non-dihydropyridine calcium channel blockers 1
  • Second-line options (if persistent symptoms):
    • Add mavacamten (adults only), OR
    • Add disopyramide (with AV nodal blocking agent), OR
    • Proceed to septal reduction therapy at experienced centers 1

This represents a fundamental change from the 2020 guidelines, where mavacamten was not yet available as an option. 1

Combination Therapy Approach

The 2024 AHA/ACC guidelines recommend mavacamten can be added to existing beta-blocker or calcium channel blocker therapy, though the European guidelines suggest it may also be used as monotherapy in patients intolerant to first-line agents. 1

Long-Term Efficacy Data

Sustained Gradient Reduction

The most compelling recent evidence comes from the VALOR-HCM 128-week extension study, which demonstrated that only 15.7% of severely symptomatic patients initially referred for septal reduction therapy ultimately required or remained eligible for the procedure after long-term mavacamten treatment. 3 This represents a dramatic reduction in the need for invasive interventions.

Key hemodynamic improvements at 128 weeks:

  • Resting LVOT gradient reduction: 38.2 mmHg 3
  • Valsalva LVOT gradient reduction: 59.4 mmHg 3
  • 80.5% of patients achieved ≥1 NYHA class improvement 3
  • 48.1% achieved ≥2 NYHA class improvement 3

Extended Follow-Up Through 180 Weeks

The MAVA-LTE study provides the longest follow-up data available, showing sustained benefits through 180 weeks (nearly 3.5 years): 4

  • Mean resting LVOT gradient reduction: -40.3 mmHg 4
  • Mean Valsalva LVOT gradient reduction: -55.3 mmHg 4
  • Median NT-proBNP reduction: -562 ng/L 4
  • 77.9% of patients improved by ≥1 NYHA class 4
  • 91.3% of patients remained on treatment 4

Cardiac Remodeling Effects

Beyond gradient reduction, mavacamten demonstrates favorable effects on cardiac structure and function: 5

  • Improved diastolic function (lateral E/e' reduction: -5.1; septal E/e' reduction: -6.0) 5
  • Reduced left atrial volume index: -11.7 ml/m² 5
  • 23.1% achieved complete resolution of systolic anterior motion 5
  • Reductions in LV mass index 5

Safety Profile and Monitoring Requirements

LVEF Monitoring Protocol

Critical safety consideration: Mavacamten can cause heart failure due to systolic dysfunction, requiring mandatory REMS program enrollment. 2

Monitoring requirements:

  • Do NOT initiate if baseline LVEF <55% 2
  • Interrupt treatment if LVEF falls <50% or clinical status worsens 2
  • Echocardiographic assessments required before and during treatment 2

LVEF Changes in Clinical Trials

Expected LVEF dynamics:

  • Mean LVEF decrease of 4% during treatment (from 74% baseline to 70%) 2
  • At Week 180, mean LVEF was 63.9% (from 73.9% baseline) 4
  • All reductions are reversible upon drug interruption 2

Incidence of LVEF <50%

Long-term safety data shows:

  • 8.7% of patients (2.77 per 100 patient-years) experienced transient LVEF reductions to <50% requiring temporary interruption over 739 patient-years of exposure 4
  • All patients recovered LVEF ≥50% after interruption 4
  • In EXPLORER-HCM, 6% had reversible LVEF reductions <50% (median 48%, range 35-49%) 2

Real-World Safety Outcomes

A large real-world study of 2,440 patients provides important safety context: 6

  • New-onset atrial fibrillation/flutter: 5% of patients 6
  • New heart failure: 4% of patients 6
  • 13% had acute care episodes (most common: HF 26%, AF 24%) 6
  • Median follow-up: 8 months 6

The VALOR-HCM extension reported new-onset atrial fibrillation in 10.2% (4.55 per 100 patient-years) over 128 weeks. 3

Critical Drug Interactions and Contraindications

Absolute Contraindications

Do NOT use mavacamten with: 2

  • Moderate to strong CYP2C19 inhibitors (e.g., omeprazole, esomeprazole)
  • Strong CYP3A4 inhibitors
  • Moderate to strong CYP2C19 inducers
  • Moderate to strong CYP3A4 inducers

These combinations either increase heart failure risk (inhibitors) or reduce efficacy (inducers). 2

Pregnancy Contraindication

Mavacamten is absolutely contraindicated in pregnancy due to teratogenic effects. 1, 2

Reproductive counseling requirements:

  • Confirm absence of pregnancy before initiating 2
  • Use effective contraception during treatment and for 4 months after last dose 2
  • Combined hormonal contraceptives with ethinyl estradiol and norethindrone are acceptable 2
  • Other combined hormonal contraceptives may be less effective; add barrier methods 2

Negative Inotrope Interactions

Close medical supervision and LVEF monitoring required when initiating or increasing doses of negative inotropes (e.g., verapamil, diltiazem, disopyramide) in patients on mavacamten. 2 Avoid certain combinations of multiple negative inotropes. 2

Discontinuation in Advanced Disease

Mavacamten MUST be discontinued in patients who develop persistent systolic dysfunction (LVEF <50%). 1 This is a Class 1 recommendation reflecting the drug's mechanism of action—further reducing contractility in an already failing ventricle would be harmful.

Patient Selection Considerations

Ideal Candidates

Based on the totality of evidence, mavacamten is most appropriate for:

  • Adults with symptomatic obstructive HCM (NYHA II-III) 2
  • Persistent symptoms despite beta-blockers or calcium channel blockers 1
  • LVEF ≥55% 2
  • Patients who wish to avoid or are not candidates for septal reduction therapy 3
  • Ability to comply with REMS program monitoring requirements 2

Real-World Patient Characteristics

The Italian early access program revealed that real-world patients are older and have more advanced disease compared to trial populations: 7

  • Mean age 61.4 years (vs. younger trial cohorts) 7
  • Lower baseline LVEF (66% vs. 74% in EXPLORER-HCM) 7
  • Higher left atrial volume index (51.1 vs. 40.5 ml/m²) 7
  • Only 22% were septal reduction therapy candidates 7

This suggests mavacamten provides benefit even in patients with more advanced phenotypes who are not surgical candidates. 7

CYP2C19 Genotyping Considerations

While mavacamten is primarily metabolized by CYP2C19, recent evidence suggests genotyping may have limited clinical utility: 8

  • No significant differences in clinical outcomes between intermediate, normal, and rapid metabolizers 8
  • Gradient reductions were similar across CYP2C19 groups 8
  • Time to optimization showed non-significant trends 8

Clinical implication: Routine CYP2C19 genotyping is not necessary for most patients, though dose adjustments based on clinical and echocardiographic response remain essential. 8

Special Populations

Active Malignancy

A case report demonstrates mavacamten can be safely used during active chemotherapy, with dramatic symptomatic improvement (LVOT gradient 115→10 mmHg within 4 weeks) without interrupting cancer treatment. 9 This expands the potential use in complex comorbid scenarios where quality of life is paramount. 9

Comparative Efficacy: Meta-Analysis Data

A 2025 meta-analysis of cardiac myosin inhibitors (including mavacamten and aficamten) across 1,406 patients confirms: 10

  • Resting LVOT gradient reduction: -57.27 mmHg 10
  • Post-Valsalva LVOT gradient reduction: -55.87 mmHg 10
  • 1.94-fold increased likelihood of ≥1 NYHA class improvement 10
  • KCCQ-CSS improvement: +6.60 points 10
  • NT-proBNP reduction: -13.35 10
  • Cardiac troponin I reduction: -11.90 10
  • Modest LVEF decrease: -4.74% 10

Adverse events were increased (RR 1.07), particularly hypertension (RR 2.19). 10

Common Adverse Events

The most frequent adverse reactions (>5% and more common than placebo) are: 2

  • Dizziness: 27% 2
  • Syncope: 6% 2

These likely reflect the hemodynamic changes from gradient reduction and should prompt evaluation for over-treatment or orthostatic hypotension.

Key Clinical Pitfalls to Avoid

  1. Do not initiate in patients with LVEF <55% - this is a hard stop based on FDA labeling and safety data 2

  2. Do not overlook drug interactions - specifically over-the-counter PPIs (omeprazole, esomeprazole) which are contraindicated 2

  3. Do not continue in pregnancy - absolute contraindication due to teratogenicity 1, 2

  4. Do not use in systolic dysfunction - must discontinue if LVEF persistently <50% 1

  5. Do not skip REMS enrollment - this is mandatory for prescribers, patients, and pharmacies 2

  6. Do not assume all patients need septal reduction - 84.3% of VALOR patients avoided surgery at 128 weeks 3

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

Is it safe to use Camzyos (mavacamten) and losartan together in patients with Hypertrophic Cardiomyopathy (HCM)?
What are the criteria for initiating mevacamptan (Mevacamptan) in patients with Hypertrophic Obstructive Cardiomyopathy (HOCM)?
What are the differences between lacunar infarct (LACI) and partial anterior circulation infarct (PACI)?
What is the appropriate management for a postoperative ICU patient in their late 80s with an arterial blood gas showing primary respiratory alkalosis (pH 7.55, PaCO₂ 29 mm Hg, PaO₂ 236 mm Hg, HCO₃⁻ 25.6 mmol/L) and hemoglobin 8.4 g/dL?
In a patient nine weeks after laser hemorrhoidoplasty for stage III internal hemorrhoids with an anal skin tag, are routine anal dilations required?
Which intranasal spray is recommended for relief of nasal congestion?
What are the current 2026 recommendations for early recognition, fluid resuscitation, antimicrobial therapy, vasopressor use, source control, and post‑acute care of sepsis and septic shock?
How is a surgical pericardial window performed and managed postoperatively for a large or recurrent pericardial effusion?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question